London: More Than 70 million people suffer from migraines worldwide and the quality of treatment for grief is far from ideal.
The triptana class is considered the gold standard in the treatment of migraine, but despite the dramatic effects on daily life faced by migraine patients, a new report by the independent market analyst Datamonitor has revealed that due to restrictions Within the national health systems, some patients do not get the best treatment available.
70 million lives affected
A migraine is a primary neurobiological disorder, manifested as recurrent attacks, which usually last from four to 72 hours. It is estimated that between 5 and 12% of the world population suffers from migraine, about 74 million people in the seven main pharmaceutical markets *, while between 23% and 42% of migraineurs report more than 24 attacks.
In the previous 12 months. The attacks, which can greatly interfere with the daily life of patients, include unilateral throbbing headache of moderate to severe intensity, and also usually involve nausea, sometimes vomiting and / or photo and phonophobia (sensitivity to light and sound ).
However, about half of migraineurs do not seek medical advice, and among those who do, only 3-19% have prescribed triptans, according to Datamonitor’s central nervous system analyst Emma Travis. “The most commonly used current treatment is simple analgesics such as Excedrin, which are used by 20-50% of patients, but the current treatment against migraine is only effective in 20-30% of patients. Not surprisingly, Datamonitor’s research has also indicated that only 20-50% of patients are satisfied with their current treatment. ”
Triptans the cornerstone
Although the triptana class is considered the well-established cornerstone of migraine therapy, there is a significant delay between the patient’s first experience of migraine symptoms and the use of triptans. Predominantly first-line therapy.
It uses simple analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs), despite the lack of sustained effect against migraine observed with these products and the risk of rebound headaches, says Travis. “Datamonitor believes that.
By educating both primary care providers (PCP) and patients, the growth in the wider and earlier use of
The triptana class will be accelerated. ”
Despite the fact that triptans are not always prescribed as first-line treatment (mostly for economic purposes and not for medical reasons) the opinion leaders with whom Datamonitor spoke remain convinced that they are the most effective medicine:
“[Triptans] are the most effective drugs without any doubt, you can use them through several routes, which is also very important in clinical practice, nasal route, mouth ingestion, even orally with a formulation of wafer or subcutaneous. ”
Opinion leader spoken by Datamonitor
“All my patients, or 99% of my patients are given a triptan option,”
Opinion leader spoken by Datamonitor
However, the good news for patients is that the use of triptans will soon accelerate with the arrival of generics.
in the market. Oral forms of the sumatriptan of GlaxoSmithKline (the first triptan launched on the market and still the
the best seller of the class) will lose the protection of the patent of 2006 and 2009 in the EU and EE. UU., Respectively.
It is inevitable that these cheaper generics will take market share from the more expensive and branded triptans, says Travis.
“A cheaper generic triptan would allow more migraine patients to access the best available medication, however, it is an accusation in modern health services that are no longer as widely used as possible.
While pragmatism must dictate health spending to a certain extent, given the dramatic effect that migraine has
“In the patients’ daily lives, one could reasonably argue that they should get the best medication available.”